This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).
Age >21 years old
Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS/MPN)
Being considered for alloHCT
Able to provide informed consent
Age >18 years old
Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters."
Caregiver may be paid/professional or informal caregiver
Able to provide informed consent